Ipsen gets European rights to GTx's Acapodene; ends deal
Executive Summary
Ipsen has licensed from GTx (men's health) exclusive rights to develop and market the cancer drug Acapodene (toremifene citrate) in Europe in all indications excluding breast cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice